Wealth Enhancement Advisory Services LLC Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Wealth Enhancement Advisory Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,913 shares of the biotechnology company’s stock after acquiring an additional 39 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in United Therapeutics were worth $1,761,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Brooklyn Investment Group bought a new position in United Therapeutics in the third quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the third quarter worth $82,000. Values First Advisors Inc. bought a new stake in United Therapeutics during the 3rd quarter valued at $90,000. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the sale, the chief financial officer now owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This trade represents a 54.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,630 shares of company stock valued at $54,371,916 in the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $364.70 on Wednesday. The business’s 50-day simple moving average is $370.22 and its two-hundred day simple moving average is $352.98. The company has a market cap of $16.28 billion, a PE ratio of 16.02, a PEG ratio of 1.05 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the firm earned $5.38 earnings per share. United Therapeutics’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on UTHR. Jefferies Financial Group raised their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 8th. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.